Na+ -H+ exchanger, pH regulation and cancer

Recent Patents on Anti-Cancer Drug Discovery

Volumn 8, Issue 1, 2013, Pages 85-99

  Reshkin, Stephan J ^a   Cardone, Rosa A ^a   Harguindey, Salvador ^b  

^a UNIVERSITY OF BARI   (Italy)

^b Institute of Clinical Biology and Metabolism   (Spain)

Author keywords

Amiloride; Angiogenesis; Cariporide; Growth factors; HOE642; Invasion; MDR; NHE1; pH and cancer; Proton transport in cancer; Tumor microenvironment

Indexed keywords

AMILORIDE; AMILORIDE DERIVATIVE; BEVACIZUMAB; CARIPORIDE; CILENGITIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENIPORIDE; ERLOTINIB; GROWTH FACTOR RECEPTOR; IMATINIB; N AMIDINO 1,4 DIMETHYL 1H INDOLE 2 CARBOXAMIDE; PHENOXAZINE DERIVATIVE; PLACEBO; PROTEINASE; PYRAZINE DERIVATIVE; SODIUM PROTON EXCHANGE PROTEIN; SODIUM PROTON EXCHANGE PROTEIN 1; ZONIPORIDE;

ACID BASE BALANCE; ANTIANGIOGENIC THERAPY; CANCER INHIBITION; CANCER INVASION; CANCER RESISTANCE; CANCER THERAPY; CELL PH; CELLULAR DISTRIBUTION; COLON CANCER; DRUG DOSE COMPARISON; DRUG STRUCTURE; EXTRACELLULAR MATRIX; GLIOMA; HEART INFARCTION; HEART PROTECTION; HUMAN; HYPERTHERMIC THERAPY; IC 50; MALIGNANT TRANSFORMATION; METASTASIS; METASTASIS INHIBITION; NEOPLASM; NONHUMAN; ONCOGENE; OXIDATIVE PHOSPHORYLATION; PH; PRIORITY JOURNAL; REVIEW; TUMOR GROWTH; TUMOR MICROENVIRONMENT; UNSTABLE ANGINA PECTORIS;

EID: 84875430250     PISSN: 15748928     EISSN: None     Source Type: Journal    
DOI: 10.2174/1574892811308010085     Document Type: Review

References (159)

1. Harguindey S, Arranz JL, Wahl ML, Orive G, Reshkin SJ. Proton transport inhibitors as potentially selective anticancer drugs. Anti- cancer Res 2009; 29(6): 2127-2136.
2. + antiporter in the etiopatho-genesis and treatment of cancer. Two faces of the same coin-one single nature. Biochim Biophys Acta 2005; 1756(1): 1-24.
3. + exchanger in metastasis. Nat Rev Cancer 2005; 5(10): 786-795.
4. Calderon-Montano JM, Burgos-Moron E, Perez-Guerrero C, Sal-vador J, Robles A, Lopez-Lazaro M. Role of the intracellular pH in the metabolic switch between oxidative phosphorylation and aerobic glycolysis - relevance to cancer. WebmedCentral Cancer 2011; 2(3): WMC001716.
5. Porporato PE, Dhup S, Dadhich RK, Copetti T, Sonveaux P. Anti-cancer targets in the glycolytic metabolism of tumors: A comprehensive review. Front Pharmacol 2011; 2: 49.
6. Smallbone K, Gatenby RA, Maini PK. Mathematical modelling of tumor acidity. J Theor Biol 2008; 255(1): 106-112.
7. Martin NK, Gaffney EA, Gatenby RA, Maini PK. Tumor-stromal interactions in acid-mediated invasion: A mathematical model. J Theor Biol 2010; 267(3): 461-470.
8. Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordon-Cardo C, et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003; 3(6): 537-549.
9. Parks SK, Chiche J, Pouyssegur J. pH control mechanisms of tumor survival and growth. J Cell Physiol 2011; 226(2): 299-308.
10. + exchanger-dependent intracellular alka-linization is an early event in malignant transformation and plays an essential role in the development of subsequent transformation-associated phenotypes. FASEB J 2000; 14(14): 2185-2197.
11. Mitchell P, Moyle J. Respiration-driven proton translocation in rat liver mitochondria. Biochem J 1967; 105(3): 1147-1162.
12. Murer H, Hopfer U, Kinne R. Sodium/proton antiport in brush-border-membrane vesicles isolated from rat small intestine and kidney. Biochem J 1976; 154(3): 597-604.
13. + antiporter. Cell 1989; 56(2): 271-280.
14. Fliegel L. Regulation of the Na(+)/H(+) exchanger in the healthy and diseased myocardium. Expert Opin Ther Targets 2009; 13(1): 55-68.
15. Boedtkjer E, Bunch L, Pedersen SF. Physiology, pharmacology and pathophysiology of the pH regulatory transport proteins NHE1 and NBCn1: Similarities, differences, and implications for cancer therapy. Curr Pharm Des 2012; 18(10): 1345-1371.
16. + exchanger in renal microvillus membrane vesicles. Nature 1982; 299(5879): 161-163.
17. Meima ME, Webb BA, Witkowska HE, Barber DL. The sodium-hydrogen exchanger NHE1 is an Akt substrate necessary for actin filament reorganization by growth factors. J Biol Chem 2009; 284(39): 26666-266675.
18. Baumgartner M, Patel H, Barber DL. Na(+)/H(+) exchanger NHE1 as plasma membrane scaffold in the assembly of signaling complexes. Am J Physiol Cell Physiol 2004; 287(4): C844-850.
19. Meima ME, Mackley JR, Barber DL. Beyond ion translocation: Structural functions of the sodium-hydrogen exchanger isoform-1. Curr Opin Nephrol Hypertens 2007; 16(4): 365-372.
20. Stock C, Ludwig FT, Schwab A. Is the multifunctional Na(+)/H(+) exchanger isoform 1 a potential therapeutic target in cancer? Curr Med Chem 2011; 19(5): 647-660.
21. + exchanger. J Biol Chem 2011; 286(15):13096-13105.
22. + exchanger, NHE1: Structure, regulation, and cellular actions. Annu Rev Pharmacol Toxicol 2002; 42: 527-552.
23. Tominaga T, Barber DL. Na-H exchange acts downstream of RhoA to regulate integrin-induced cell adhesion and spreading. Mol Biol Cell 1998; 9(8): 2287-2303.
24. + exchanger (NHE1) creates acidic microenvironments leading to hyaluronidase-2 and cathepsin B activation and breast tumor cell invasion. J Biol Chem 2004; 279(26): 26991-27007.
25. + exchanger gene family. J Nephrol 2002; 15 (Suppl 5): S3-21.
26. Hoffmann EK, Pedersen SF. Cell volume homeostatic mechanisms: Effectors and signalling pathways. Acta Physiol (Oxf) 2011; 202(3): 465-485.
27. + exchanger NHE1 in stress-induced signal transduction: Implications for cell proliferation and cell death. Pflugers Arch 2006; 452(3): 249-259.
28. Lucien F, Brochu-Gaudreau K, Arsenault D, Harper K, Dubois CM. Hypoxia-induced invadopodia formation involves activation of NHE-1 by the p90 ribosomal S6 kinase (p90RSK). PLoS One 2011; 6(12): e28851.
29. + exchanger isoform 1 is mediated through phosphorylation of amino acids Ser726 and Ser729. Am J Physiol Cell Physiol 2008; 295(4): C883-896.
30. Vaupel P, Okunieff P, Neuringer LJ. Blood flow, tissue oxygena-tion, pH distribution, and energy metabolism of murine mammary adenocarcinomas during growth. Adv Exp Med Biol 1989; 248: 835-845.
31. Reshkin SJ, Bellizzi A, Albarani V, Guerra L, Tommasino M, Paradiso A, et al. Phosphoinositide 3-kinase is involved in the tumor-specific activation of human breast cancer cell Na(+)/H(+) exchange, motility, and invasion induced by serum deprivation. J Biol Chem 2000; 275(8): 5361-5369.
32. Cardone RA, Bellizzi A, Busco G, Weinman EJ, Dell'Aquila ME, Casavola V, et al. The NHERF1 PDZ2 domain regulates PKA-RhoA-p38-mediated NHE1 activation and invasion in breast tumor cells. Mol Biol Cell 2007; 18(5): 1768-1780.
33. Busco G, Cardone RA, Greco MR, Bellizzi A, Colella M, Antelmi E, et al. NHE1 promotes invadopodial ECM proteolysis through acidification of the peri-invadopodial space. FASEB J 2010; 24(10): 3903-3915.
34. + exchange in pulmonary arterial smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 2005; 289(5): L867-874.
35. Yang X, Wang D, Dong W, Song Z, Dou K. Inhibition of Na(+)/H(+) exchanger 1 by 5-(N-ethyl-N-isopropyl) amiloride reduces hypoxia-induced hepatocellular carcinoma invasion and mo-tility. Cancer Lett 2010; 295(2): 198-204.
36. Brisson L, Gillet L, Calaghan S, Besson P, Le Guennec JY, Roger S, et al. Na(V)1.5 enhances breast cancer cell invasiveness by increasing NHE1-dependent H(+) efflux in caveolae. Oncogene 2011; 30(17): 2070-2076.
37. Gillet L, Roger S, Besson P, Lecaille F, Gore J, Bougnoux P, et al. Voltage-gated sodium channel activity promotes cysteine cathep-sin-dependent invasiveness and colony growth of human cancer cells. J Biol Chem 2009; 284(13): 8680-8691.
38. Lacroix J, Poet M, Maehrel C, Counillon L. A mechanism for the activation of the Na/H exchanger NHE-1 by cytoplasmic acidification and mitogens. EMBO Rep 2004; 5(1): 91-96.
39. Fuster D, Moe OW, Hilgemann DW. Steady-state function of the ubiquitous mammalian Na/H exchanger (NHE1) in relation to di-mer coupling models with 2Na/2H stoichiometry. J Gen Physiol 2008; 132(4): 465-480.
40. Hulikova A, Vaughan-Jones RD, Swietach P. Dual role of CO2/HCO3(-) formula buffer in the regulation of intracellular pH of three-dimensional tumor growths. J Biol Chem 2011; 286(16): 13815-13826.
41. Grillon E, Farion R, Fablet K, De Waard M, Tse CM, Donowitz M, et al. The spatial organization of proton and lactate transport in a rat brain tumor. PLoS One 2011; 6(2): e17416.
42. Li X, Liu Y, Alvarez BV, Casey JR, Fliegel L. A novel carbonic anhydrase II binding site regulates NHE1 activity. Biochemistry 2006; 45(7): 2414-2424.
43. + exchanger. J Biol Chem 2002; 277(39): 36085-36091.
44. +, HCO3(-) cotransporter NBCn1, regulates motility of MCF7 breast cancer cells expressing constitutively active ErbB2. Cancer Lett 2011; 317(2): 172-183.
45. Lauritzen G, Jensen MB, Boedtkjer E, Dybboe R, Aalkjaer C, Nylandsted J, et al. NBCn1 and NHE1 expression and activity in DeltaNErbB2 receptor-expressing MCF-7 breast cancer cells: Contributions to pHi regulation and chemotherapy resistance. Exp Cell Res 2010; 316(15): 2538-2553.
46. - cotransport in migration of transformed renal epithelial cells. J Physiol 2005; 568(Pt 2): 445-458.
47. Doppler W, Jaggi R, Groner B. Induction of v-mos and activated Ha-ras oncogene expression in quiescent NIH 3T3 cells causes in-tracellular alkalinisation and cell-cycle progression. Gene 1987; 54(1): 147-153.
48. Hagag N, Lacal JC, Graber M, Aaronson S, Viola MV. Microinjec-tion of ras p21 induces a rapid rise in intracellular pH. Mol Cell Biol 1987; 7(5): 1984-1988.
49. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011; 144(5): 646-674.
50. Warburg O. On respiratory impairment in cancer cells. Science 1956; 124(3215): 269-270.
51. Kuwata F, Suzuki N, Otsuka K, Taguchi M, Sasai Y, Wakino H, et al. Enzymatic regulation of glycolysis and gluconeogenesis in rabbit periodontal ligament under various physiological pH conditions. J Nihon Univ Sch Dent 1991; 33(2): 81-90.
52. Peak M, al-Habori M, Agius L. Regulation of glycogen synthesis and glycolysis by insulin, pH and cell volume. Interactions between swelling and alkalinization in mediating the effects of insulin. Bio-chem J 1992; 282(Pt 3): 797-805.
53. Dietl K, Renner K, Dettmer K, Timischl B, Eberhart K, Dorn C, et al. Lactic acid and acidification inhibit TNF secretion and glyco-lysis of human monocytes. J Immunol 2010; 184(3): 1200-1209.
54. Chiche J, Brahimi-Horn MC, Pouyssegur J. Tumor hypoxia induces a metabolic shift causing acidosis: A common feature in cancer. J Cell Mol Med 2010; 14(4): 771-794.
55. + exchanger precedes apoptotic events in the MNK45 and MNK74 gastric cancer cell lines treated with 2-aminophenoxazine-3-one. Oncol Rep 2011; 25(2): 341-346.
56. Chen JL, Merl D, Peterson CW, Wu J, Liu PY, Yin H, et al. Lactic acidosis triggers starvation response with paradoxical induction of TXNIP through MondoA. PLoS Genet 2010; 6(9) pii: e1001093.
57. Putney LK, Barber DL. Expression profile of genes regulated by activity of the Na-H exchanger NHE1. BMC Genomics 2004; 5(1): 46.
58. Griffiths JR. Are cancer cells acidic? Br J Cancer 1991; 64(3): 425-427.
59. +-ATPases as a new strategy against cancer. Cancer Res 2007; 67(22): 10627-10630.
60. Chiche J, Ilc K, Laferriere J, Trottier E, Dayan F, Mazure NM, et al. Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH. Cancer Res 2009; 69(1): 358-368.
61. Supuran CT. Carbonic anhydrases: Novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov 2008; 7(2): 168-181.
62. Chiche J, Le Fur Y, Vilmen C, Frassineti F, Daniel L, Halestrap AP, et al. In vivo pH in metabolic-defective Ras-transformed fibro-blast tumors: Key role of the monocarboxylate transporter, MCT4, for inducing an alkaline intracellular pH. Int J Cancer 2011; 130(7): 1511-1520.
63. Pouyssegur J, Dayan F, Mazure NM. Hypoxia signalling in cancer and approaches to enforce tumor regression. Nature 2006; 441(7092): 437-443.
64. Chiang AC, Massague J. Molecular basis of metastasis. N Engl J Med 2008; 359(26): 2814-2823.
65. + exchanger 1 and its clinicopathologic significance in hepa-tocellular carcinoma. Med Oncol 2010; 27(4): 1109-1113.
66. McLean LA, Roscoe J, Jorgensen NK, Gorin FA, Cala PM. Malignant gliomas display altered pH regulation by NHE1 compared with nontransformed astrocytes. Am J Physiol Cell Physiol 2000; 278(4): C676-688.
67. Schlappack OK, Zimmermann A, Hill RP. Glucose starvation and acidosis: Effect on experimental metastatic potential, DNA content and MTX resistance of murine tumor cells. Br J Cancer 1991; 64(4): 663-670.
68. Rofstad EK. Microenvironment-induced cancer metastasis. Int J Radiat Biol 2000; 76(5): 589-605.
69. Moellering RE, Black KC, Krishnamurty C, Baggett BK, Stafford P, Rain M, et al. Acid treatment of melanoma cells selects for invasive phenotypes. Clin Exp Metastasis 2008; 25(4): 411-425.
70. Martinez-Zaguilan R, Seftor EA, Seftor RE, Chu YW, Gillies RJ, Hendrix MJ. Acidic pH enhances the invasive behavior of human melanoma cells. Clin Exp Metastasis 1996; 14(2): 176-186.
71. Giusti I, D'Ascenzo S, Millimaggi D, Taraboletti G, Carta G, Franceschini N, et al. Cathepsin B mediates the pH-dependent proinvasive activity of tumor-shed microvesicles. Neoplasia 2008; 10(5): 481-488.
72. Rofstad EK, Mathiesen B, Kindem K, Galappathi K. Acidic extracellular pH promotes experimental metastasis of human melanoma cells in athymic nude mice. Cancer Res 2006; 66(13): 6699-6707.
73. Macheda ML, Rogers S, Best JD. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol 2005; 202(3): 654-662.
74. Gambhir SS. Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer 2002; 2(9): 683-693.
75. Hawkins RA, Phelps ME. PET in clinical oncology. Cancer Metastasis Rev 1988; 7(2): 119-142.
76. Weber WA, Avril N, Schwaiger M. Relevance of positron emission tomography (PET) in oncology. Strahlenther Onkol 1999; 175(8): 356-373.
77. Chambers AF. The metastatic process: Basic research and clinical implications. Oncol Res 1999; 11(4): 161-168.
78. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer 2009; 9(4): 239-252.
79. Gatenby RA, Gawlinski ET, Gmitro AF, Kaylor B, Gillies RJ. Acid-mediated tumor invasion: A multidisciplinary study. Cancer Res 2006; 66(10): 5216-5223.
80. Kraus M, Wolf B. Implications of acidic tumor microenvironment for neoplastic growth and cancer treatment: A computer analysis. Tumor Biol 1996; 17(3): 133-154.
81. Mason SD, Joyce JA. Proteolytic networks in cancer. Trends Cell Biol 2011; 21(4): 228-237.
82. Briozzo P, Morisset M, Capony F, Rougeot C, Rochefort H. In vitro degradation of extracellular matrix with Mr 52,000 cathepsin D secreted by breast cancer cells. Cancer Res 1988; 48(13): 3688-3692.
83. Rozhin J, Sameni M, Ziegler G, Sloane BF. Pericellular pH affects distribution and secretion of cathepsin B in malignant cells. Cancer Res 1994; 54(24): 6517-6525.
84. Kato Y, Nakayama Y, Umeda M, Miyazaki K. Induction of 103-kDa gelatinase/type IV collagenase by acidic culture conditions in mouse metastatic melanoma cell lines. J Biol Chem 1992; 267(16): 11424-11430.
85. Chen KH, Tung PY, Wu JC, Chen Y, Chen PC, Huang SH, et al. An acidic extracellular pH induces Src kinase-dependent loss of beta-catenin from the adherens junction. Cancer Lett 2008; 267(1): 37-48.
86. Taves J, Rastedt D, Canine J, Mork D, Wallert MA, Provost JJ. Sodium hydrogen exchanger and phospholipase D are required for alpha1-adrenergic receptor stimulation of metalloproteinase-9 and cellular invasion in CCL39 fibroblasts. Arch Biochem Biophys 2008; 477(1): 60-66.
87. Lin Y, Wang J, Jin W, Wang L, Li H, Ma L, et al. NHE1 mediates migration and invasion of HeLa cells via regulating the expression and localization of MT1-MMP. Cell Biochem Funct 2011 doi: 10.1002/cbf.1815. [Epub ahead of print].
88. Lin Y, Chang G, Wang J, Jin W, Wang L, Li H, et al. NHE1 mediates MDA-MB-231 cells invasion through the regulation of MT1-MMP. Exp Cell Res 2011; 317(14): 2031-2040.
89. Provost JJ, Rastedt D, Canine J, Ngyuen T, Haak A, Kutz C, et al. Urokinase plasminogen activator receptor induced non-small cell lung cancer invasion and metastasis requires NHE1 transporter expression and transport activity. Cell Oncol (Dordr) 2012; [Epub ahead of print].
90. Steffan JJ, Coleman DT, Cardelli JA. The HGF-met signaling axis: Emerging themes and targets of inhibition. Curr Protein Pept Sci 2011; 12(1): 12-22.
91. Stock C, Schwab A. Protons make tumor cells move like clockwork. Pflugers Arch 2009; 458(5): 981-992.
92. Weaver AM. Invadopodia: Specialized cell structures for cancer invasion. Clin Exp Metastasis 2006; 23(2): 97-105.
93. Murphy DA, Courtneidge SA. The 'ins' and 'outs' of podosomes and invadopodia: Characteristics, formation and function. Nat Rev Mol Cell Biol 2011; 12(7): 413-426.
94. Buccione R, Caldieri G, Ayala I. Invadopodia: Specialized tumor cell structures for the focal degradation of the extracellular matrix. Cancer Metastasis Rev 2009; 28(1-2): 137-149.
95. Magalhaes MA, Larson DR, Mader CC, Bravo-Cordero JJ, Gil-Henn H, Oser M, et al. Cortactin phosphorylation regulates cell invasion through a pH-dependent pathway. J Cell Biol 2011; 195(5): 903-920.
96. Clark ES, Whigham AS, Yarbrough WG, Weaver AM. Cortactin is an essential regulator of matrix metalloproteinase secretion and extracellular matrix degradation in invadopodia. Cancer Res 2007; 67(9): 4227-4235.
97. Attanasio F, Caldieri G, Giacchetti G, van Horssen R, Wieringa B, Buccione R. Novel invadopodia components revealed by differential proteomic analysis. Eur J Cell Biol 2010; 90(2-3): 115-127.
98. Parekh A, Ruppender NS, Branch KM, Sewell-Loftin MK, Lin J, Boyer PD, et al. Sensing and modulation of invadopodia across a wide range of rigidities. Biophys J 2011; 100(3): 573-582.
99. Alexander NR, Branch KM, Parekh A, Clark ES, Iwueke IC, Guelcher SA, et al. Extracellular matrix rigidity promotes invado-podia activity. Curr Biol 2008; 18(17): 1295-1299.
100. Stock C, Cardone RA, Busco G, Krahling H, Schwab A, Reshkin SJ. Protons extruded by NHE1: Digestive or glue? Eur J Cell Biol 2008; 87(8-9): 591-599.
101. Denker SP, Huang DC, Orlowski J, Furthmayr H, Barber DL. Direct binding of the Na-H exchanger NHE1 to ERM proteins regulates the cortical cytoskeleton and cell shape independently of H(+) translocation. Mol Cell 2000; 6(6): 1425-1436.
102. Denker SP, Barber DL. Cell migration requires both ion transloca-tion and cytoskeletal anchoring by the Na-H exchanger NHE1. J Cell Biol 2002; 159(6): 1087-1096.
103. + exchanger in rat renal cortical tubules. Am J Physiol 1997; 273(3 Pt 1): C1064-1074.
104. Masereel B, Pochet L, Laeckmann D. An overview of inhibitors of Na(+)/H(+) exchanger. Eur J Med Chem 2003; 38(6): 547-554.
105. Laeckmann D, Rogister F, Dejardin JV, Prosperi-Meys C, Geczy J, Delarge J, et al. Synthesis and biological evaluation of aroylgua-nidines related to amiloride as inhibitors of the human platelet Na(+)/H(+) exchanger. Bioorg Med Chem 2002; 10(6): 1793-1804.
106. + exchange inhibitor and its effects in cardiac ischaemia. Br J Pharmacol 1993; 109(2): 562-568.
107. Scholz W, Albus U, Counillon L, Gogelein H, Lang HJ, Linz W, et al. Protective effects of HOE642, a selective sodium-hydrogen exchange subtype 1 inhibitor, on cardiac ischaemia and reperfu-sion. Cardiovasc Res 1995; 29(2): 260-268.
108. + antiporter inhibitors. J Med Chem 1997; 40(13): 2017-2034.
109. Gumina RJ, Buerger E, Eickmeier C, Moore J, Daemmgen J, Gross GJ. Inhibition of the Na(+)/H(+) exchanger confers greater cardio-protection against 90 minutes of myocardial ischemia than ischemic preconditioning in dogs. Circulation 1999; 100(25): 2519-2526; discussion 469-472.
110. Guzman-Perez A, Wester RT, Allen MC, Brown JA, Buchholz AR, Cook ER, et al. Discovery of zoniporide: A potent and selective sodium-hydrogen exchanger type 1 (NHE-1) inhibitor with high aqueous solubility. Bioorg Med Chem Lett 2001; 11(6): 803-807.
111. Kuribayashi Y, Itoh N, Kitano M, Ohashi N. Cerebroprotective properties of SM-20220, a potent Na(+)/H(+) exchange inhibitor, in transient cerebral ischemia in rats. Eur J Pharmacol 1999; 383(2): 163-168.
112. 2+-overload. J Cardiovasc Pharmacol 2000; 35(6): 855-862.
113. Ahmad S, Doweyko LM, Dugar S, Grazier N, Ngu K, Wu SC, et al. Arylcyclopropanecarboxyl guanidines as novel, potent, and selective inhibitors of the sodium hydrogen exchanger isoform-1. J Med Chem 2001; 44(20): 3302-3310.
114. Aihara K, Hisa H, Sato T, Yoneyama F, Sasamori J, Yamaguchi F, et al. Cardioprotective effect of TY-12533, a novel Na(+)/H(+) exchange inhibitor, on ischemia/reperfusion injury. Eur J Pharmacol 2000; 404(1-2): 221-229.
115. Fukumoto S, Imamiya E, Kusumoto K, Fujiwara S, Watanabe T, Shiraishi M. Novel, non-acylguanidine-type Na(+)/H(+) exchanger inhibitors: Synthesis and pharmacology of 5-tetrahydroquinoliny-lidene aminoguanidine derivatives. J Med Chem 2002; 45(14): 3009-3021.
116. Kleemann, H.-W. Pentafluorosulfanylbenzoylguanidines, processes for their preparation, their use as medicaments or diagnostic aids, and medicaments comprising them. US8008352 (2011).
117. Lal, B., Bal-Tembe, S., Ghosh, U., Jain, A.K., More, T., Ghate, A., Trivedi, J., Parikh, S. Tricyclic guanidine derivatives as sodium-proton exchange inhibitors. US8183234 (2012).
118. Uemoto, K., Takayanagi, K., Kazayama, S. Cyclohepta[b]pyridine-3-carbonylguanidine derivative and pharmaceutical product containing same. US7875625 (2011).
119. Gorin, F.A., Nantz, M.H. Amino acid and peptide conjugates of amiloride and methods of use thereof. US7863415 (2011).
120. Lorrain J, Briand V, Favennec E, Duval N, Grosset A, Janiak P, et al. Pharmacological profile of SL 59.1227, a novel inhibitor of the sodium/hydrogen exchanger. Br J Pharmacol 2000; 131(6): 1188-1194.
121. Che XF, Zheng CL, Akiyama S, Tomoda A. 2-Aminophenoxazine-3-one and 2-amino-4,4alpha-dihydro-4alpha,7-dimethyl-3H-pheno-xazine-3-one cause cellular apoptosis by reducing higher intracellu-lar pH in cancer cells. Proc Jpn Acad Ser B Phys Biol Sci 2011; 87(4): 199-213.
122. Atwal KS, O'Neil SV, Ahmad S, Doweyko L, Kirby M, Dorso CR, et al. Synthesis and biological activity of 5-aryl-4-(4-(5-methyl-1H-imidazol-4-yl)piperidin-1-yl)pyrimidine analogs as potent, highly selective, and orally bioavailable NHE-1 inhibitors. Bioorg Med Chem Lett 2006; 16(18): 4796-4799.
123. Goldfeder A. Some recent developments in the cancer field. J Am Med Womens Assoc 1953; 8(4): 124-130.
124. + exchanger activity is increased in doxorubicin-resistant human colon cancer cells and its modulation modifies the sensitivity of the cells to doxorubicin. Int J Cancer 2005; 115(6): 924-929.
125. Matthews H, Ranson M, Kelso MJ. Anti-tumor/metastasis effects of the potassium-sparing diuretic amiloride: An orally active anti-cancer drug waiting for its call-of-duty? Int J Cancer 2011; doi: 10.1002/ijc.26156. [Epub ahead of print].
126. Rupprecht HJ, vom Dahl J, Terres W, Seyfarth KM, Richardt G, Schultheibeta HP, et al. Cardioprotective effects of the Na(+)/H(+) exchange inhibitor cariporide in patients with acute anterior myo-cardial infarction undergoing direct PTCA. Circulation 2000; 101(25): 2902-2908.
127. Boyce SW, Bartels C, Bolli R, Chaitman B, Chen JC, Chi E, et al. Impact of sodium-hydrogen exchange inhibition by cariporide on death or myocardial infarction in high-risk CABG surgery patients: Results of the CABG surgery cohort of the GUARDIAN study. J Thorac Cardiovasc Surg 2003; 126(2): 420-427.
128. Chaitman BR. A review of the GUARDIAN trial results: Clinical implications and the significance of elevated perioperative CK-MB on 6-month survival. J Card Surg 2003; 18 (Suppl 1): 13-20.
129. Mentzer RM, Jr., Bartels C, Bolli R, Boyce S, Buckberg GD, Chaitman B, et al. Sodium-hydrogen exchange inhibition by cari-poride to reduce the risk of ischemic cardiac events in patients undergoing coronary artery bypass grafting: Results of the EXPEDITION study. Ann Thorac Surg 2008; 85(4): 1261-1270.
130. Zeymer U, Suryapranata H, Monassier JP, Opolski G, Davies J, Rasmanis G, et al. The Na(+)/H(+) exchange inhibitor eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction. Results of the evaluation of the safety and cardioprotective effects of eniporide in acute myocardial infarction (ESCAMI) trial. J Am Coll Cardiol 2001; 38(6): 1644-1650.
131. + exchanger regulation for cardiac protection: A RSKy approach? Curr Opin Pharmacol 2008; 8(2): 133-140.
132. + Exchanger: A target for Therapeutic Intervention in Cerebral Ischemia. In: Annunziato L, (Ed.) New Strategies in Stroke Intervention Ionic Transporters, Pumps, and New Channels: Humana Press; 2010. pp. 113-128.
133. Huber V, De Milito A, Harguindey S, Reshkin SJ, Wahl ML, Ra-uch C, et al. Proton dynamics in cancer. J Transl Med 2010; 8: 57.
134. + exchanger (NHE) NHE isoform 1 in human breast cancer cells. Clin Cancer Res 2003; 9(6): 2366-2373.
135. Chang WH, Liu TC, Yang WK, Lee CC, Lin YH, Chen TY, et al. Amiloride modulates alternative splicing in leukemic cells and re-sensitizes Bcr-AblT315I mutant cells to imatinib. Cancer Res 2011; 71(2): 383-392.
136. Cohen MH, Johnson JR, Chen YF, Sridhara R, Pazdur R. FDA drug approval summary: Erlotinib (Tarceva) tablets. Oncologist 2005; 10(7): 461-466.
137. Stupp R, Ruegg C. Integrin inhibitors reaching the clinic. J Clin Oncol 2007; 25(13): 1637-1638.
138. Gilbert MR, Kuhn J, Lamborn KR, Lieberman F, Wen PY, Mehta M, et al. Cilengitide in patients with recurrent glioblastoma: The results of NABTC 03-02, a phase II trial with measures of treatment delivery. J Neurooncol 2012; 106(1): 147-153.
139. Kerbel RS. Tumor angiogenesis. N Engl J Med 2008; 358(19): 2039-2049.
140. de Groot JF, Fuller G, Kumar AJ, Piao Y, Eterovic K, Ji Y, et al. Tumor invasion after treatment of glioblastoma with bevacizumab: Radiographic and pathologic correlation in humans and mice. Neuro Oncol 2010; 12(3): 233-242.
141. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350(23): 2335-2342.
142. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009; 15(3): 220-231.
143. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009; 15(3): 232-239.
144. Brahimi-Horn C, Pouyssegur J. The role of the hypoxia-inducible factor in tumor metabolism growth and invasion. Bull Cancer 2006; 93(8): E73-80.
145. Lu X, Kang Y. Hypoxia and hypoxia-inducible factors: Master regulators of metastasis. Clin Cancer Res 2010; 16(24): 5928-5935.
146. + exchanger 1 with cariporide (HOE642) reduces the hypoxia-induced invasion of human tongue squamous cell carcinoma. Int J Oral Maxillofac Surg 2012.
147. Xu L, Fukumura D, Jain RK. Acidic extracellular pH induces vascular endothelial growth factor (VEGF) in human glioblastoma cells via ERK1/2 MAPK signaling pathway: Mechanism of low pH-induced VEGF. J Biol Chem 2002; 277(13): 11368-11374.
148. + exchanger. Leuk Res 2007; 31(4): 507-514.
149. Avery RL, Connor TB, Jr., Farazdaghi M. Systemic amiloride inhibits experimentally induced neovascularization. Arch Ophthal-mol 1990; 108(10): 1474-6.
150. + exchanger in cancer angiogenesis and antiangiogenesis. Br J Cancer 2003; 89(8): 1395-1399.
151. Lyons JC, Kim GE, Song CW. Modification of intracellular pH and thermosensitivity. Radiat Res 1992; 129(1): 79-87.
152. Song CW, Lin JC, Lyons JC. Antitumor effect of interleukin 1 alpha in combination with hyperthermia. Cancer Res 1993; 53(2): 324-328.
153. Liu JC, Fox MH. Modification of intracellular pH and thermotoler-ance development by amiloride. Int J Hyperthermia 1995; 11(4): 511-522.
154. + antiport function. Radiother Oncol 1996; 40(1): 75-83.
155. Kitai R, Kabuto M, Kubota T, Kobayashi H, Matsumoto H, Haya-shi S, et al. Sensitization to hyperthermia by intracellular acidification of C6 glioma cells. J Neurooncol 1998; 39(3): 197-203.
156. Czepan M, Rakonczay ZJr, Varro A, Steele I, Dimaline R, Lertkowit N, et al. NHE1 activity contributes to migration and is necessary for proliferation of human gastric myofibroblasts. Pflugers Arch 2012; 463(3): 459-475.
157. Coaxum SD, Garnovskaya MN, Gooz M, Baldys A, Raymond JR. Epidermal growth factor activates Na(+/)H(+) exchanger in podo-cytes through a mechanism that involves Janus kinase and calmodulin. Biochim Biophys Acta 2009; 1793(7): 1174-1181.
158. + exchanger NHE1 by post-translational regulation that is important for cervical cancer cell invasiveness. J Cell Physiol 2008; 214(3): 810-819.
159. Linz, W., Schindler, U. Pharmaceutical composition comprising a sodium hydrogen exchange inhibitor and an angiotensin converting enzyme inhibitor. US8088799 (2012).